195 related articles for article (PubMed ID: 34615851)
1. Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound.
Giovannucci TA; Salomons FA; Haraldsson M; Elfman LHM; Wickström M; Young P; Lundbäck T; Eirich J; Altun M; Jafari R; Gustavsson AL; Johnsen JI; Dantuma NP
Cell Death Dis; 2021 Oct; 12(10):914. PubMed ID: 34615851
[TBL] [Abstract][Full Text] [Related]
2. The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.
Ao N; Chen Q; Liu G
Comb Chem High Throughput Screen; 2017; 20(5):403-413. PubMed ID: 28699494
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.
Buckley DL; Crews CM
Angew Chem Int Ed Engl; 2014 Feb; 53(9):2312-30. PubMed ID: 24459094
[TBL] [Abstract][Full Text] [Related]
6. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
[TBL] [Abstract][Full Text] [Related]
7. Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Jarvius M; Fryknäs M; D'Arcy P; Sun C; Rickardson L; Gullbo J; Haglund C; Nygren P; Linder S; Larsson R
Biochem Biophys Res Commun; 2013 Feb; 431(2):117-23. PubMed ID: 23318177
[TBL] [Abstract][Full Text] [Related]
8. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
Asher G; Lotem J; Tsvetkov P; Reiss V; Sachs L; Shaul Y
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15065-70. PubMed ID: 14634213
[TBL] [Abstract][Full Text] [Related]
9. Proteasome substrate receptors and their therapeutic potential.
Osei-Amponsa V; Walters KJ
Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
[TBL] [Abstract][Full Text] [Related]
10. Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
Mooneyham A; Bazzaro M
Methods Mol Biol; 2017; 1513():49-59. PubMed ID: 27807830
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.
Coughlin K; Anchoori R; Iizuka Y; Meints J; MacNeill L; Vogel RI; Orlowski RZ; Lee MK; Roden RB; Bazzaro M
Clin Cancer Res; 2014 Jun; 20(12):3174-86. PubMed ID: 24727327
[TBL] [Abstract][Full Text] [Related]
12. A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1.
Moscovitz O; Tsvetkov P; Hazan N; Michaelevski I; Keisar H; Ben-Nissan G; Shaul Y; Sharon M
Mol Cell; 2012 Jul; 47(1):76-86. PubMed ID: 22793692
[TBL] [Abstract][Full Text] [Related]
13. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
[TBL] [Abstract][Full Text] [Related]
14. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
15. The Capture of a Disabled Proteasome Identifies Erg25 as a Substrate for Endoplasmic Reticulum Associated Degradation.
Buck TM; Zeng X; Cantrell PS; Cattley RT; Hasanbasri Z; Yates ME; Nguyen D; Yates NA; Brodsky JL
Mol Cell Proteomics; 2020 Nov; 19(11):1896-1909. PubMed ID: 32868373
[TBL] [Abstract][Full Text] [Related]
16. A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.
Ling XH; Wang SK; Huang YH; Huang MJ; Duh CY
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30347865
[TBL] [Abstract][Full Text] [Related]
17. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Driscoll JJ; Dechowdhury R
Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
[TBL] [Abstract][Full Text] [Related]
18. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
19. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
[TBL] [Abstract][Full Text] [Related]
20. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.
Hyer ML; Milhollen MA; Ciavarri J; Fleming P; Traore T; Sappal D; Huck J; Shi J; Gavin J; Brownell J; Yang Y; Stringer B; Griffin R; Bruzzese F; Soucy T; Duffy J; Rabino C; Riceberg J; Hoar K; Lublinsky A; Menon S; Sintchak M; Bump N; Pulukuri SM; Langston S; Tirrell S; Kuranda M; Veiby P; Newcomb J; Li P; Wu JT; Powe J; Dick LR; Greenspan P; Galvin K; Manfredi M; Claiborne C; Amidon BS; Bence NF
Nat Med; 2018 Feb; 24(2):186-193. PubMed ID: 29334375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
